| Literature DB >> 35268807 |
Yang Guo1, Ben-Yin Zhang2, Yan-Feng Peng2, Leng Chee Chang3, Zhan-Qiang Li1, Xin-Xin Zhang4, De-Jun Zhang1,2.
Abstract
Oxytropis falcata Bunge is a plant used in traditional Tibetan medicine, with reported anti-inflammatory and antioxidants effects and alleviation of myocardial ischemia reperfusion injury (MIRI). However, the underlying mechanism against MIRI and the phytochemical composition of O. falcata are vague. One fraction named OFF1 with anti-MIRI activity was obtained from O. falcata, and the chemical constituents were identified by ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS). The potential targets and signaling pathways involved in the action of O. falcata against MIRI were predicted by network pharmacology analysis, and its molecular mechanism on MIRI was determined by in vitro assays. The results revealed that flavonoids are the dominant constituents of OFF1. A total of 92 flavonoids reported in O. falcata targeted 213 potential MIRI-associated factors, including tumor necrosis factor (TNF), prostaglandin-endoperoxide synthase 2 (PTGS2), and the NF-κB signaling pathway. The in vitro assay on H9c2 cardiomyocytes subjected to hypoxia/reoxygenation injury confirmed that the flavonoids in OFF1 reduced myocardial marker levels, apoptotic rate, and the inflammatory response triggered by oxidative stress. Moreover, OFF1 attenuated MIRI by downregulating the ROS-mediated JNK/p38MAPK/NF-κB pathway. Collectively, these findings provide novel insights into the molecular mechanism of O. falcata in alleviating MIRI, being a potential therapeutic candidate.Entities:
Keywords: JNK/p38MAPK/NF-κB; Oxytropis falcata Bunge; flavonoids; myocardial ischemia reperfusion injury; network pharmacology
Mesh:
Substances:
Year: 2022 PMID: 35268807 PMCID: PMC8911915 DOI: 10.3390/molecules27051706
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Effects of OFF1 on H9c2 cell injury. (A) Cell viability of H9C2 cells subjected to different treatments (n= 5). (B,C) Levels of cardiac markers under different treatments (n = 5). (D) Representative immunoblot showing the expression of Caspase9, Caspase3, Bax, and Bcl-2 (n = 3). (E–I) Semi-quantitative analyses of Caspase9, Caspase3, Bax, and Bcl-2 proteins (n = 3). Results are expressed as mean ± SD. * p < 0.05, ** p < 0.01 versus the control group; # p < 0.05, ## p < 0.01 versus the H/R group. Con, control group; H/R, hypoxia/reoxygenation; Dil, diltiazem; OFF1, prepared fraction from O. falcata.
Metabolites tentatively identified in OFF1 by UHPLC–MS in positive and negative ion modes.
| No. | Name | Molecular | Error | MW | ESI+/− | MS/MS |
|---|---|---|---|---|---|---|
| 1 | Daidzein | C15H10O4 | 1.77 | 254.0584 | 255.1022/253.1437 | 186.9758, 204.9867, 219.2112, 237.2218 |
| 2 | Pinocembrin | C15H12O4 | 1.08 | 256.0738 | 257.0046/ | 215.9778, 256.2641, 210.9722, 233.0177 |
| 3 | 7-Hydroxyflavone | C15H10O3 | 2.16 | 238.06351 | 239.1283/238.8211 | 195.1230, 239.1073 |
| 4 | Isoliquiritigenin | C15H12O4 | 1.44 | 256.07393 | 257.0046/– | 192.9624, 210.9722, 215.9778, 233.0177 |
| 5 | 2,4,4′-Trihydroxydihydrochalcone | C15H14O4 | −3.4 | 258.08833 | –/257.1943 | 219.8445, 256.1910 |
| 6 | Strobopinin | C16H14O4 | −2.57 | 270.0885 | –/269.2114 | 225.1019, 228.9878, 221.5644, 232.3254, |
| 7 | Sakuranetin | C16H14O5 | 2.24 | 286.08476 | 287.0556/– | 121.0292, 153.0187, 165.0190 |
| 8 | Formononetin | C16H12O4 | 1.02 | 268.0738 | 269.2116/267.0655 | 123.1166, 155.1437, 251.2016, 2215.1795 |
| 9 | Bryaflavan | C17H18O6 | 0.58 | 318.1105 | 319.2024/– | 163.1125, 219.1749 |
| 10 | Luteolin | C15H10O6 | −2.7 | 286.0470 | –/285.9279 | 157.8609, 198.8836, 213.9066, 219.8449 |
| 11 | Genistein | C15H10O5 | 2.36 | 270.0535 | 271.0971/269.2114 | 144.0830, 217.1947, 225.1028, 235.2047 |
| 12 | Naringenin | C15H12O5 | 2.45 | 272.0691 | 273.0887/271.2271 | 200.9438, 205.9934, 215.1287, 245.0923, |
| 13 | Hispidulin | C16H12O6 | −3.07 | 300.0625 | –/299.2583 | 123.0438, 134.8927, 160.8404, 180.5528, 253.9687, 262.5875 |
| 14 | Glycitein | C16H12O5 | 0.52 | 284.0686 | 285.0764/283.2633 | 166.9462, 192.9622, 214.9700, 210.9728 |
| 15 | 2′,4′-Dihydroxychalcone | C15H12O3 | −3.4 | 240.0235 | –/241.1943 | 219.8445, 256.1910 |
| 16 | Miquelianin | C21H18O13 | 3.03 | 478.0762 | 479.0735/477.0154 | 303.0505, 229.0504, 153.0190 |
| 17 | Isorhamnetin 3-glucuronide | C22H20O13 | 2.4 | 492.0916 | 493.3905/491.2122 | 153.0189, 302.0428, 317.0661 |
| 18 | Lilaline | C20H17NO7 | 2.34 | 383.1014 | 384.1614/– | 206.0816, 118.0656, 160.0769, 188.0707, 248.0921 |
| 19 | Kaempferol 3-glucuronide | C21H18O12 | −2.2 | 462.0788 | –/461.0716 | 2253.0503, 261.9223, 320.8129, 357.7877 |
| 20 | Maackiain | C16H12O5 | 0.42 | 284.0686 | 285.0764/– | 214.9700, 192.9622, 210.9729, 184.9571 |
| 21 | 4’’’’-Acetylsagittatin A | C34H40O19 | 2.57 | 752.2183 | –/751.2076 | 298.0475, 607.1785, 426.9629, 395.3199 |
| 22 | Brosimacutin C | C20H22O5 | −2.89 | 342.1457 | –/341.1079 | 216.9878, 254.9855, 270.5942, 337.8138 |
| 23 | Phloretin | C15H14O5 | −2.51 | 274.0834 | –/273.0159 | 134.4794, 146.6030, 169.0068, 179.8389 |
| 24 | (S)-Equol | C15H14O3 | 1.78 | 242.0947 | 243.1915/– | 111.0926, 180.1755, 228.1808, 107.0865 |
| 25 | Isovolubilin | C23H24O9 | −2.24 | 444.1410 | –/443.1184 | 193.0493, 249.0610, 267.0711, 149.0591 |
| 26 | Astragalin | C21H20O11 | −2.37 | 448.0995 | –/447.0060 | 78.9576, 148.9995, 179.0102, 96.9678 |
| 27 | Rhamnetin | C16H12O7 | 1.65 | 316.0588 | 317.6330/– | 167.0349, 243.0658,274.0481, 302.0421 |
| 28 | Scrophulein | C17H14O6 | 1.71 | 314.07958 | 315.0506/– | 287.0554, 231.0657, 259.0604, 203.0712 |
| 29 | Isoquercetin | C21H20O12 | −2.18 | 464.0945 | –/463.0872 | 301.1073, 405.6862, 135.0440, 160.8422, |
| 30 | Isomucronulatol | C17H18O5 | −2.03 | 302.0258 | –/301.2122 | 113.0277, 120.0007, 181.0848 |
| 31 | Rutin | C27H30O16 | 2.07 | 610.1547 | 611.1619/– | 303.0504, 97.0289 |
Figure 2Screening of targets in MIRI. (A) Overlapping flavonoid-related and MIRI-related targets by Venn diagram. (B) Protein–protein interaction network and key crossover targets.
Figure 3Active compound–MIRI–target network. The yellow hexagons indicate the disease, the green V indicate 213 targets, the purple squares indicate 92 active compounds, and the blue square indicates drug.
Figure 4(A) GO enrichment analysis of the overlapping targets. (B) KEGG pathway annotation of the overlapping targets. (C) KEGG pathway analysis of the overlapping targets.
Figure 5(A–D) Inflammatory cytokines levels in the indicated groups (n = 5). (E–H) Oxidative stress markers in the indicated groups (n = 5). (I,J) Representative images of immunostained cells showing the nuclear localization of Nrf2 (n = 3) (400x magnification). The blue fluorescence indicates the nucleus, and the red fluorescence indicates Nrf2. (K) ROS levels in the indicated groups (n = 5). Results are expressed as mean ± SD. * p < 0.05, ** p < 0.01 versus the control group; ## p < 0.01 versus the H/R group. Con, control group; H/R, hypoxia/reoxygenation; Dil, diltiazem; OFF1, prepared fraction from O. falcata.
Figure 6OFF1 alleviated H9c2 injury by the inhibition of the NF-κB pathway. (A) NF-κBp65 levels in the indicated groups (n = 5). (B) Representative immunoblots showing the expression of NF-κBp65 and IκB (n = 3). (C–F) Semi-quantitative analysis of NF-κBp65 and p-NF-κBp65 in the indicated groups. (E) Representative images of immunostained cells showing the nuclear localization of NF-κBp65 (n = 3) (400× magnification). (F) Relative fluorescence intensity of nuclear Nrf2. The blue fluorescence represents the nucleus, and the green fluorescence represents NF-κBp65. Results are expressed as mean ± SD. ** p < 0.01 versus the control group; # p < 0.05, ## p < 0.01 versus the H/R group. Con, control group; H/R, hypoxia/reoxygenation; Dil, diltiazem; OFF1, prepared fraction from O. falcata.
Figure 7OFF1 attenuated H9c2 injury through the regulation of the MAPK pathway. (A) Representative immunoblot showing the expression of JNK and p38 (n = 3). (B–E) Semi-quantitative analysis of p-JNK, JNK, p-p38, and p38 in the indicated groups. Results are expressed as mean ± SD. ** p < 0.01 versus the control group; # p < 0.05, ## p < 0.01 versus the H/R group. Con, control group; H/R, hypoxia/reoxygenation; Dil, diltiazem; OFF1, prepared fraction from O. falcata.
Figure 8OFF1 protects cardiomyocytes from H/R injury by regulating the ROS-mediated JNK/p38MAPK/NF-κB pathway.